Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2017

Kim Dong-Wan, Garon Edward B, Jatoi Aminah, Keefe Dorothy M, Lacouture Mario E, Sonis Stephen, Gernhardt Diana, Wang Tao, Giri Nagdeep, Doherty Jim P, Nadanaciva Sashi, O'Connell Joseph, Sbar Eric, Cho Byoung Chul

Abstract excerpt

OBJECTIVES: Dacomitinib is a pan-HER inhibitor for advanced non-small-cell lung cancer (NSCLC). We explored the impact of a planned 4-day dacomitinib dose interruption on plasma exposure of dacomitinib and adverse events (AEs) of interest in Cohort III of the ARCHER 1042 study. MATERIALS AND METHODS: Patients, treatment-naïve for advanced NSCLC with EGFR activating mutations, received oral dacomitinib 45mg QD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to ErbB Receptors

Share to Neoplasm Staging

Share to Quinazolines

Share to Quinazolinones

Share to Republic of Korea

Source

Open in PubMed Open full text

Identifiers

PMID: 28285698
DOI: 10.1016/j.lungcan.2017.01.021
PMCID: PMC5552055

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).PMID 28285698Read ↗

Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive Non-Small-Cell Lung CancerSemantic proximity Read ↗

Tumor growth inhibition modeling to support the starting dose for dacomitinib.Semantic proximity Read ↗

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).Semantic proximity Read ↗

Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.Semantic proximity Read ↗

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.Semantic proximity Read ↗

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).Semantic proximity Read ↗

Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.Semantic proximity Read ↗

Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.Semantic proximity Read ↗

Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.Semantic proximity Read ↗

The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.